Imiquimod
(Synonyms: 咪喹莫特; R 837) 目录号 : GC16407A TLR7 agonist
Cas No.:99011-02-6
Sample solution is provided at 25 µL, 10mM.
IC50: Imiquimod activates toll-like receptor 7 (EC50 2.1 μM) on immune cells and also enables an OGF-mediated block of cell proliferation (IC50 2 μM) [1].
Toll-like receptor 7, also known as TLR7, is protein that in humans is encoded by the TLR7 gene. It is a member of the toll-like receptor (TLR) family. The TLR family plays an important role in pathogen recognition and activation of innate immunity. Imiquimod is a prescription medication that acts as an immune response modifier activating toll-like receptor 7. It is marketed by Meda AB, Graceway Pharmaceuticals, and iNova Pharmaceuticals under the trade names Aldara and Zyclara, and by Farmacoquímica Médica (FQM) in Brazil as Ixium.
In vitro: Results from a previous study demonstrate that imiquimod were capable of inducing interleukin-12 and interferon-g in mouse and human cell cultures. Imiquimod was also found to inhibit IL-4 and IL-5 production in mouse and human culture systems. These data suggested that imiquimod might have clinical utility in diseases where cellmediated immune responseswere important and in diseases associated with overexpression of IL-4 or IL-5, such as atopic disease. [2].
In vivo: The findings from animal study suggested that imiquimod could inhibit the airway inflammation of asthma animals by reducing GATA-3 mRNA and protein expression and increasing T-bet, STAT(6) mRNA and protein expression [3].
Clinical trial: Imiquimod is a patient-applied cream used to treat certain diseases of the skin, including skin cancers (basal cell carcinoma, Bowen's disease, superficial squamous cell carcinoma, some superficial malignant melanomas, and actinic keratosis) as well as genital warts (condylomata acuminata). However, Imiquimod is generally secondary to surgery, because surgery has a better chance to effectively treat at least some forms of skin cancer. Imiquimod has been tested for treatment of molluscum contagiosum. Two large randomized controlled trials, however, found no evidence of effectiveness of imiquimod in treating children with molluscum contagiosum, and concerning adverse effects were also noted. Imiquimod has also been tested for treatment of vulvar intraepithelial neoplasia, common warts that have proven difficult to treat, and vaginal intraepithelial neoplasia.
IC50: Imiquimod能够激活免疫细胞上的Toll样受体7(EC50为2.1μM),并使OGF介导的细胞增殖受阻(IC50为2μM)[1]。 Toll样受体7,又称TLR7,是人类中由TLR7基因编码的一种蛋白质。它是Toll样受体(TLR)家族的成员。TLR家族在病原体识别和激活先天免疫方面发挥重要作用。Imiquimod是一种处方药,作为免疫反应修饰剂,可以激活Toll样受体7。它由Meda AB、Graceway Pharmaceuticals和iNova Pharmaceuticals在Aldara和Zyclara等品牌下销售,由巴西Farmacoquímica Médica(FQM)作为Ixium销售。
体外研究:以前的研究结果表明,imiquimod能够在小鼠和人类细胞培养中诱导白细胞介素-12和干扰素-g的产生。Imiquimod还发现能够抑制小鼠和人类文化系统中IL-4和IL-5的产生。这些数据表明,imiquimod可能在细胞介导的免疫反应重要和与IL-4或IL-5过度表达相关的疾病(如变应性疾病)的治疗中具有临床效用[2]。
体内:动物研究结果表明,Imiquimod可以通过减少GATA-3 mRNA和蛋白表达以及增加T-bet、STAT(6)mRNA和蛋白表达来抑制哮喘动物的气道炎症 [3]。
临床试验:Imiquimod是一种患者自行使用的乳膏,用于治疗皮肤癌(基底细胞癌、Bowen病、表浅性鳞状细胞癌、某些表浅性恶性黑色素瘤和日光性角化症)以及生殖器疣(尖锐湿疣)。然而,Imiquimod通常是手术的辅助治疗,因为手术有更好的机会有效地治疗至少某些形式的皮肤癌。Imiquimod已经被测试用于治疗软疣。然而,两项大型随机对照试验没有发现Imiquimod在治疗儿童软疣方面的有效性,并且注意到有关不良反应的问题。Imiquimod还被测试用于治疗阴道上皮内瘤变、难以治疗的普通疣和阴道上皮内瘤变。
Reference:
[1] Zagon IS, Donahue RN, Rogosnitzky M, McLaughlin PJ. Imiquimod upregulates the opioid growth factor receptor to inhibit cell proliferation independent of immune function. Exp Biol Med (Maywood). 2008;233(8):968-79.
[2] Wagner TL, Ahonen CL, Couture AM, Gibson SJ, Miller RL, Smith RM, Reiter MJ, Vasilakos JP, Tomai MA. Modulation of TH1 and TH2 cytokine production with the immune response modifiers, R-848 and imiquimod. Cell Immunol. 1999;191(1):10-9.
[3] Yin KS, Jin SX, Bian T, Wu QZ, Wang X, Yao X. The effects of imiquimod on an animal model of asthma. Zhonghua Jie He He Hu Xi Za Zhi. 2007;30(7):509-17.
Cas No. | 99011-02-6 | SDF | |
别名 | 咪喹莫特; R 837 | ||
化学名 | 1-(2-methylpropyl)imidazo[4,5-c]quinolin-4-amine | ||
Canonical SMILES | CC(C)CN1C=NC2=C1C3=CC=CC=C3N=C2N | ||
分子式 | C14H16N4 | 分子量 | 240.3 |
溶解度 | insoluble in Water ;insoluble in Ethanol;DMSO:3 mg/mL (12.48 mM; warmed with 50ºC water bath) | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 4.1615 mL | 20.8073 mL | 41.6146 mL |
5 mM | 0.8323 mL | 4.1615 mL | 8.3229 mL |
10 mM | 0.4161 mL | 2.0807 mL | 4.1615 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet